Journal of Affective Disorders
Volume 105, Issue 1 , Pages 1-14 , January 2008

Restoring melancholia in the classification of mood disorders

  • Michael Alan Taylor

      Affiliations

    • Professor of Psychiatry Emeritus, Rosalind Franklin University of Medicine and Science, North Chicago Illinois, United States
    • Adjunct Clinical Professor of Psychiatry, University of Michigan, Ann Arbor, United States
    • 1407 Lincoln Avenue, Ann Arbor MI 48104. Tel.: +734 998 1383
    • ,
  • Max Fink

      Affiliations

    • Professor of Psychiatry and Neurology Emeritus, State University of New York at Stony Brook, United States
    • Corresponding Author InformationCorresponding author. P.O. Box 457, St. James, New York 11780-0457. Tel.: +1 631 862 6651.

Received 8 January 2007 ,Revised 21 May 2007 ,Accepted 29 May 2007.

References 

  1. Abercrombie HC, Schaefer SM, Larson CL, Oakes TR, Lindgren KA, Holden JE, et al. Metabolic rate in the right amygdala predicts negative affect in depressed patients. Neuro Report. 1998;9:3301–3307
  2. Abrams R. Electroconvulsive therapy. 4th ed. New York: Oxford University Press; 2002;
  3. Akhondzadeh S, Faraji H, Sadeghi M, Afkham K, Fakhrzadeh H, Kamalipour A. Double-blind comparison of fluoxetine and nortriptyline in the treatment of moderate to severe major depression. J. Clin. Pharm. Ther. 2003;28:379–384
  4. Alvarez E, Perez-Sola V, Perez-Blanco J, Queralto JM, Torrubia R, Noguera R. Predicting outcome of lithium added to antidepressants in resistant depression. J. Affect. Disord. 1997;42:179–186
  5. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. Fourth edition. Washington D.C.: American Psychiatric Association; 1994;
  6. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J. Affect. Disord. 2000;58:19–36
  7. Anderson IM, Tomenson BM. The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J. Psychopharmacol. 1994;8:238–249
  8. Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB. The role of corticotropin-releasing factor in depression and anxiety disorders. J. Endocrinol. 1999;160:1–12
  9. Ayuso-Mateos JL, Vazquez-Barquero JL, Dowrick C, Lehtinen V, Dalgard OS, Casey P, et al. Depressive disorders in Europe: prevalence figures from the ODIN study. Br. J. Psychiatry. 2001;179:308–316
  10. Baethge C, Salvatore P, Baldessarini RJ. Cyclothymia, a circular mood disorder. Hist. Psychiatr. 2003;14:377–399
  11. Bagby RM, Ryder AG, Cristi C. Psychosocial and clinical predictors of response to pharmacotherapy for depression. J. Psychiatry Neurosci. 2002;27:250–257
  12. Baldessarini RJ, Tondo L. Suicide risk and treatments for patients with bipolar disorder. JAMA. 2003;290:1517–1519
  13. Barbui C, Hotopf M. Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomized controlled trials. Br. J. Psychiatry. 2001;178:129–144
  14. Bauer M, Dopfmer S. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J. Clin. Psychopharmacol. 1999;19:427–434
  15. Benca RM, Obermeyer WH, Thisted RA, Gillin JC. Sleep and psychiatric disorders: a meta-analysis. Arch. Gen. Psychiatry. 1992;49:651–668
  16. Benazzi F. Psychomotor changes in melancholic and atypical depression: unipolar and bipolar II subtypes. Psychiatry Res. 2002;112:211–220
  17. Bertelsen A, Harvald B, Hauge M. A Danish twin study of manic–depressive disorders. Br. J. Psychiatry. 1977;130:330–351
  18. Biver F, Goldman S, Delvenne V, Luxen A, De Maertelaer V, Hubain P, et al. Frontal and parietal metabolic disturbances in unipolar depression. Biol. Psychiatry. 1994;36:381–388
  19. Blazer D, Swartz M, Woodbury M, Manton KG, Hughes D, George LK. Depressive symptoms and depressive diagnoses in a community population. Use of a new procedure for analysis of psychiatric classification. Arch. Gen. Psychiatry. 1988;45:1078–1084
  20. Blazer DG, Kessler RL, McGonagle KA, Swartz MS. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am. J. Psychiatry. 1994;151:979–986
  21. Block M, Schwartzman Y, Bonne O, Lerer B. Concurrent treatment of nonresistant major depression with desipramine and lithium: a double-blind, placebo-controlled study. J. Clin. Psychopharmacol. 1977;17:44–48
  22. Bremner JD, Innis RB, Salomon RM, Staib LH, Ng CK, Miller HL, et al. Positron emission tomography measurement of cerebral metabolic correlates of tryptophan depletion-induced depressive relapse. Arch. Gen. Psychiatry. 1997;54:364–374
  23. Bremner JD, Naraya M, Anderson ER, Staib LH, Miller HL, Charney DS. Hippocampal volume reduction in major depression. Am. J. Psychiatry. 2000;157:115–118
  24. Brody AL, Saxena S, Mandelkern MA, Fairbanks LA, Ho ML, Baxter LR. Brain metabolic changes associated with symptom factor improvement in major depressive disorder. Biol. Psychiatry. 2001;50:171–178
  25. Brody AL, Saxena S, Stoessel P, Gillies LA, Fairbanks LA, Alborzian S, et al. Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy. Arch. Gen. Psychiatry. 2000;58:631–640
  26. Buchsbaum MS, Wu J, Siegel BV, Hackett E, Trenary M, Abel L, et al. Effect of sertraline on regional metabolic rate in patients with affective disorder. Biol. Psychiatry. 1997;41:15–22
  27. Burgess S, Geddes J, Hawton K, Townsend E, Jamison K, Goodwin G. Lithium for maintenance treatment of mood disorders. Cochrane Database Syst. Rev. 2001;1–44[CD003013]
  28. Burvill PW. An appraisal of the NIMH Epidemiologic Catchment Area Program. Aust. N.Z.J. Psychiatry. 1987;21:175–184
  29. Carroll BJ, Curtis GC, Mendels J. Neuroendocrine regulation in depression. I. Limbic system-adrenocortical dysfunction. Arch. Gen. Psychiatry. 1976;33:1039–1044
  30. Carroll BJ, Feinberg M, Greden JF, Haskett RF, James NM, Steiner M, et al. Diagnosis of endogenous depression. Comparison of clinical, research and neuroendocrine criteria. J. Affect. Dis. 1980;177–194
  31. Cassano GB, Rucci P, Frank E, Fagiolini A, Dell'Osso L, Shear MK, et al. The mood spectrum in unipolar and bipolar disorder: arguments for a unitary approach. Am. J. Psychiatry. 2004;161:1264–1269
  32. Cheetham SC, Crompton MR, Katone CL, Horton RW. Brain 5-HT 1 binding sites in depressed suicides. Psychopharmacol. 1990;102:544–548
  33. Cipriani A, Barbui C, Geddes JR. Suicide, depression, and antidepressants. BMJ. 2005;330:373–374
  34. Coryell W, Schlesser M. The dexamethasone suppression test and suicide prediction. Am. J. Psychiatry. 2001;158:748–753
  35. Coryell W, Winokur G, Shea T, Maser JD, Endicott J, Akiskal HS. The long-term stability of depressive subtypes. Am. J. Psychiatry. 1994;151:199–204
  36. Danish University Antidepressant Group . Citalopram: clinical effect profile in comparison with clomipramine: a controlled multicenter study. Psychopharmacology (Berl). 1986;90:131–138
  37. Danish University Antidepressant Group . Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J. Affect. Disord. 1990;18:289–299
  38. Danish University Antidepressant Group . Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. J. Affect. Disord. 1993;28:105–116
  39. Danish University Antidepressant Group . Clomipramine dose-effect study in patients with depression: clinical end points and pharmacokinetics. Clin. Pharmacol. Ther. 1999;66:152–165
  40. Drevets WC. Functional neuroimaging studies of depression: the anatomy of melancholia. Annu. Rev. Med. 1998;49:341–361
  41. Drevets WC. Prefrontal cortical-amygdalar metabolism in major depression. In advancing from the ventral striatum to the extended amygdala: implications for neuropsychiatry and drug abuse. Ann. NY Acad. Sci., New York. 1999;614–637
  42. Drevets WC. Integration of structural and functional neuroimaging in depression research. In:  Dougherty D,  Rauch S,  Rosenbaum J editor. Psychiatric Neuroimaging Strategies: Research and Clinical Applications. Washington DC: American Psychiatric Press; 1999;
  43. Drevets WC. Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. Prog. Brain Res. 2000;126:413–431
  44. Drevets WC, Botteron K. Neuroimaging in psychiatry. In:  Guze SB editors. Adult Psychiatry. St. Louis: Mosby; 1997;p. 53–81
  45. Drevets WC, Spitznagel E, Raichle ME. Functional anatomical differences between major depressive subtypes. J. Cerebral. Blood Flow Metab. 1995;15:S93
  46. Drevets WC, Price JL, Simpson JR, Todd RD, Reich T, Vannier M, et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature. 1997;386:824–827
  47. Drevets WC, Frank E, Price JC, Kupfer DJ, Holt D, Greer PG, et al. PET imaging of serotonin 1A receptor binding in depression. Biol. Psychiatry. 1999;46:1375–1387
  48. Drevets WC, Price JL, Bardgett ME, Reich T, Todd RD, Raichle ME. Glucose metabolism in the amygdala in depression: relationship to diagnostic subtype and plasma cortisol levels. Pharmacol. Biochem. Behav. 2002;71:431–447
  49. Duffy A, Grof P, Robertson C, Alda M. The implications of genetic studies of major mood disorders in clinical practice. J. Clin. Psychiatry. 2000;61:630–637
  50. Eaton WW, Holzer CE, Von Korff M, Anthony JC, Helzer JE, George L, et al. The design of the epidemiologic catchment area surveys. The control and measure of error. Arch. Gen. Psychiatry. 1984;41:942–948
  51. Eaton WW, Kramer M, Anthony JC, Dryman A, Shapiro S, Locke BZ. The incidence of specific DIS/DSM-III mental disorders: data from the NIMH Epidemiologic Catchment Area Program. Acta. Psychiatr. Scand. 1989;79:163–178
  52. Fava M, Alpert J, Nierenberg A, Lagomasino I, Sanowalla S, Tedlow J, et al. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders or non-responders to fluoxetine. J. Clin. Psychopharmacol. 2002;22:379–387
  53. Fink M. Should the dexamethasone suppression test be resurrected?. Acta. Psychiatr. Scand. 2005;112:245–249
  54. Fink M, Taylor MA. Catatonia: A Clinician's Guide to Diagnosis and Treatment. Cambridge UK: Cambridge University Press; 2003;
  55. First MB, Zimmerman M. Including laboratory tests in DSM-V diagnostic criteria. Am. J. Psychiatry. 2006;163:2041–2042
  56. Freemantle N, Anderson IM, Young P. Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Meta-regression analysis. Br. J. Psychiatry. 2000;177:292–302
  57. Frodl T, Meisenzahl EM, Zill P, Baghai T, Rujescu D, Leinsinger G, et al. Reduced hippocampal volumes associated with the long variant of the serotonin transporter polymorphism in major depression. Arch. Gen. Psychiatry. 2004;61:177–183
  58. Furukawa T, McGuire H, Barbui C. Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review. BMJ. 2002;325:991–995
  59. Gloor P, Olivier A, Quesney LF, Andermann F, Horowitz S. The role of the limbic system in experiential phenomena of temporal lobe epilepsy. Ann. Neurol. 1982;12:129–144
  60. Gonzalez AM, Pascual J, Meana JJ, Barturen F, del Arco C, Pazos A, et al. Autoradiographic demonstration of increased alpha 2-adrenoceptor binding sites in the hippocampus and frontal cortex of depressed suicide victims. J. Neurochem. 1994;63:256–265
  61. Goodman SH, Gotlib IH. Risk for psychopathology in children of depressed mothers: a developmental model of understanding mechanisms of transmission. Psychol. Rev. 1999;106:458–490
  62. Goodwin FK, Jamison KR. Manic–depressive Illness. New York: Oxford University Press; 1990;
  63. Gray TS. Amygdaloid CRF pathways. Role in autonomic, neuroendocrine, and behavioral responses to stress. Ann. NY Acad. Sci. 1993;697:53–60
  64. Harmon-Jones E, Abramson LY, Sigelman J, Bohlig A, Hogan ME, Harmon-Jones C. Proneness to hypomania/mania symptoms or depression symptoms and asymmetrical frontal cortical responses to an anger-evoking event. J. Pers. Soc. Psychol. 2002;82:610–618
  65. Heim C, Nemeroff CB. The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies. Biol. Psychiatry. 2001;49:1023–1039
  66. Hildebrandt MG, Steyerberg EW, Stage KB, Passchier J, Kragh-Soerensen P The Danish University Antidepressant Group. Are gender differences important for the clinical effects of antidepressants?. Am. J. Psychiatry. 2003;160:1643–1650
  67. Hirayasu Y, Shenton ME, Salisbury DF, Kwon JS, Wible CG, Fischer IA, et al. Subgenual cingulate cortex volume in first-episode psychosis. Am. J. Psychiatry. 1999;156:1091–1093
  68. Hirshfeld-Becker DR, Biederman J, Calltharp S, Rosenbaum ED, Farao SV, Rosenbaum JM. Behavioral inhibition and disinhibition as hypothesized precursors to psychopathology: implications for pediatric bipolar disorder. Biol. Psychiatry. 2003;53:985–999
  69. Holsboer F. Stress, hypercortisolism and corticosteroid receptors in depression: implications for therapy. J. Affect. Disord. 2001;62:77–91
  70. Huang YY, Oquendo MA, Friedman JM, Greenhill LL, Brodsky B, Malone KM, et al. Substance abuse disorder and major depression are associated with the human 5-HT1B receptor gene (HTR1B) G861C polymorphism. Neuropsychopharmacology. 2003;28:163–169
  71. Ingraham LJ, Wender PH. Risk for affective disorder and alcohol and other drug abuse in the relatives of affectively ill adoptees. J. Affect. Disord. 1992;26:45–52
  72. Jones I, Kent L, Craddock N. The genetics of affective disorders. In:  McGuffin P,  Owen MJ,  Gottesman II editor. Psychiatric Genetics and Genomics. Oxford, England: Oxford University Press; 2002;
  73. Joyce PR, Mulder RT, Luty SE, McKenzie JM, Sullivan PF, Abbott RM, et al. Melancholia: definitions, risk factors, personality, neuroendocrine markers and differential antidepressant response. Aust. NZ J. Psychiatry. 2002;36:376–383
  74. Khan A, Detke M, Khan SRF, Mallinckrodt C. Placebo response and antidepressant clinical trial outcome. J. Nerv. Ment. Dis. 2003;191:211–218
  75. Keck ME, Holsboer F. Hyperactivity of CRH neuronal circuits as a target for therapeutic interventions in affective disorders. Peptides. 2001;22:835–844
  76. Kellner CH, Knapp RG, Petrides G, Rummans TA, Husain M, Rasmussen K, et al. Continuation ECT versus pharmacotherapy for relapse prevention in major depression: a multi-site study from CORE. Arch. Gen. Psychiatry. 2006;63:1337–1344
  77. Kendell RE. In: The Classification of Depressive Illness. London: Oxford University Press; 1968;
  78. Kendell RE. The classification of depressions: a review of contemporary confusion. Br. J. Psychiatry. 1976;129:15–28
  79. Kendler KS, Gardner CO. Boundaries of major depression: an evaluation of DSM-IV criteria. Am. J. Psychiatry. 1998;155:172–177
  80. Kendler KS, Eaves LJ, Walters EE, Neale MC, Heath AC, Kessler RC. The identification and validation of distinct depressive syndromes in a population-based sample of female twins. Arch. Gen. Psychiatry. 1996;53:391–399
  81. Kendler KS, Gardner CO, Neale MC, Prescott CA. Genetic risk factors for major depression in men and women: similar or different heritabilities and same or partly distinct genes?. Psychol. Med. 2001;31:605–616
  82. Klein DN, Lewinsohn PM, Seeley JR, Rohde P. A family study of major depressive disorder in a community sample of adolescents. Arch. Gen. Psychiatry. 2001;589:13–20
  83. Kessing LV. Endogenous, reactive and neurotic depression — diagnostic stability and long-term outcome. Psychopathology. 2004;37:124–130
  84. Kessler RC. Epidemiology of women and depression. J. Affect. Disord. 2003;74:5–13
  85. Koper JW, Stolk RP, de Lange P, Huizenga NAM, Olijn GJ, Pols HA, et al. Lack of association between five polymorphisms in the human glucocorticoid receptor gene and glucocorticoid resistance. Hum. Genet. 1997;99:663–668
  86. Kovacs M, Devlin B, Pollock M, Richards C, Mukerji P. A controlled family history study of childhood-onset depressive disorder. Arch. Gen. Psychiatry. 1997;54:613–623
  87. Leckman JF, Weissman MM, Prusoff BA, Caruso KA, Merikangas KR, Pauls DL, et al. Subtypes of depression. Arch. Gen. Psychiatry. 1984;41:845–852
  88. Lemonde S, Turecki G, Bakish D, Du L, Hrdina PD, Bown CD, et al. Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J. Neurosci. 2003;223:8788–8799
  89. Lieb R, Isensee B, Hofler M, Pfister H, Wittchen HU. Parental major depression and the risk of depression and other mental disorders in offspring. A prospective-longitudinal community study. Arch. Gen. Psychiatry. 2002;59:365–374
  90. Lopez JF, Chalmers DT, Little KY, Watson SJ. Regulation of serotonin 1A, glucorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol. Psychiatry. 1998;43:547–573
  91. Maes M, Dierckx R, Meltzer HY, Ingels M, Schotte C, Vandewoude M, et al. Regional cerebral blood flow in unipolar depression measured with Tc-99m-HMPAO single photon emission computed tomography: negative findings. Psychiatry Res. 1993;50:77–88
  92. McGuffin P, Katz R. The genetics of depression and manic–depressive disorder. Br. J. Psychiatry. 1989;155:294–304
  93. McGuffin P, Rijsdijk F, Andrew M. The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Arch. Gen. Psychiatry. 2003;60:497–502
  94. Meijer OC, de Kloet ER. Corticosterone and serotonergic neurotransmission in the hippocampus: functional implications of central corticosteroid receptor diversity. Crit. Rev. Neurobiol. 1998;12:1–20
  95. Meyer SE, Chrousos GP, Gold PW. Major depression and the stress system: a life span perspective. Dev. Psychopath. 2001;13:565–580
  96. Modell S, Lauer CJ, Schreiber W, Huber J, Krieg JC, Holsboer F. Hormonal response pattern in the combined DEX-CRH test is stable over time in subjects at high familiar risk for affective disorder. Neuropsychopharmacology. 1998;18:253–262
  97. Moldin SO, Reich T, Rice JP. Current perspectives on the genetics of unipolar depression. Behav. Genet. 1991;21:211–242
  98. Navarro V, Gasto C, Torres X, Marcos T, Pintor L. Citalopram versus nortriptyline in late-life depression: a 12-week randomized single-blind study. Acta Psychiatr. Scand. 2001;103:435–440
  99. Navarro V, Gasto C, Lomena F, Mateos JJ, Marcos T, Portella MJ. Normalization of frontal cerebral perfusion in remitted elderly major depression: a 12-month follow-up SPECT study. Neuroimage. 2002;16:781–787
  100. Navarro V, Gasto C, Lomena F, Mateos JJ, Portella MJ, Massana G, et al. Frontal cerebral perfusion after antidepressant drug treatment versus ECT in elderly patients with major depression: a 12-month follow-up control study. J. Clin. Psychiatry. 2004;65:656–661
  101. Nelson JC, Davis JM. DST studies in psychotic depression: a meta-analysis. Am. J. Psychiatry. 1997;154:1497–1503
  102. Neuman R, Geller B, Rice JP, Todd R. Increased prevalence and earlier onset of mood disorders among relatives of prepubertal versus adult probands. J. Am. Acad. Child Adolesc. Psych. 1997;36:466–473
  103. Nobler MS, Roose SP. Differential response to antidepressants in melancholic and severe depression. Psychiatr. Ann. 1998;28:84–88
  104. Nobler MS, Sackeim HA, Prohovnik I, Moeller JR, Mukherjee S, Schnur DB, et al. Regional cerebral blood flow in mood disorders, III. Treatment and clinical response. Arch. Gen. Psychiatry. 1994;51:884–897
  105. Nofzinger EA, Keshavan MS, Buysse DJ, Moore RY, Kupfer DJ, Reynolds CF. Neurobiology of sleep in relation to mental illness. In:  Charney DS,  Nestler EJ,  Bunney BS editor. Neurobiology of Mental Illness. New York: Oxford University Press; 1999;1999;p. 915–929
  106. Okun MS, Green J, Saben R, Gross R, Foote KD, Vitek JL. Mood changes with deep brain stimulation of STN and GPi: results of a pilot study. J. Neurol. Neurosurg. Psychiatry. 2003;74:1584–1586
  107. Olsson GI, von Knorring AL. Adolescent depression: prevalence in Swedish high-school students. Acta Psychiatr. Scand. 1999;99:324–331
  108. Paradiso S, Lamberty GJ, Garvey MJ, Robinson RG. Cognitive impairment in the euthymic phase of chronic unipolar depression. J. Nerv. Ment. Dis. 1997;185:748–754
  109. Parianti CM, Miller AH. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol. Psychiatry. 2001;49:391–404
  110. Parker G, Hadzi-Pavlovic D. Melancholia: a disorder of movement and mood. Cambridge UK: Cambridge University Press; 1996;
  111. Parra J, Augustijn PB, Geerts Y, Van Emde Boas W. Classification of epileptic seizures: a comparison of two systems. Epilepsia. 2001;42:476–482
  112. Paykel ES. Classification of depressed patients: a cluster-analysis derived grouping. Br. J. Psychiatry. 1971;118:275–288
  113. Paykel ES, Prusoff BA, Klerman GL, Haskell D, di Mascio A. Clinical response to amitriptyline among depressed women. J. Nerv. Ment. Dis. 1973;156:149–165
  114. Perry PJ. Pharmacotherapy for major depression with melancholic features: relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. J. Affect. Disord. 1996;20(39):1–396
  115. Petrides G, Fink M, Husain MM, Knapp R, Rush AJ, Mueller M, et al. ECT remission rates in psychotic versus non-psychotic depressed patients: a report from CORE. JECT. 2001;17:244–253
  116. Preskorn SH, Fast GA. Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. J. Clin. Psychiatry. 1991;52(suppl):23–33
  117. Preskorn SH, Burke M. Somatic therapy for major depressive disorder: selection of an antidepressant. J. Clin. Psychiatry. 1992;53(suppl):5–18
  118. Price LH, Nelson JC, Charney DS, Quinlan DM. Family history in delusional depression. J. Affect. Disord. 1984;6:109
  119. Price LH, Carpenter LL, Rasmussen SA. Drug combination strategies. In:  Amsterdam JD,  Hornig M,  Nierenberg AA editor. Treatment-Resistant Mood Disorders. Cambridge, UK: Cambridge University Press; 2001;p. 194–222
  120. Prusoff BA, Paykel ES. Typological prediction of response to amitriptyline: a replication study. Int. Pharmacopsychiatry. 1977;12:153–159
  121. Puig-Antich J, Goetz D, Davies M, Kaplan T, Davies S, Ostrow L, et al. A controlled family history study of prepubertal major depressive disorder. Arch. Gen. Psychiatry. 1989;46:406–418
  122. Raadsheer FC, Heerikuize JJ, Lucassen PJ, Hoogendijk WJ, Tilders FJ, Swaab DF. Corticotropin-releasing hormone mRNA levels in the paraventricular nucleus of patients with Alzheimer's disease and depression. Am. J. Psychiatry. 1995;152:1372–1376
  123. Rauch SL, Jenike MA, Alpert NM, Baer L, Breiter HC, Savage CR, et al. Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography. Arch. Gen. Psychiatry. 1994;51:62–70
  124. Roose SP, Glassman AH, Attia E, Woodring S. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am. J. Psychiatry. 1994;151:1735–1739
  125. Rorsman B, Grasbeck A, Hagnell O, Lanke J, Ohman R, Ojesjo L, et al. A prospective study of first-incidence depression. The Lundby Study, 1957–72. Br. J. Psychiatry. 1990;156:336–342
  126. Rothschild AJ. The hypothalamic–pituitary–adrenal axis and psychiatric illness. In:  Wolkowitz OM,  Rothschild AJ editor. Psychoneuroendocrinology: The Scientific Basis of Clinical Practice. 6:Washington DC: American Psychiatric Publishing; 2003;p. 139–163
  127. Rubin E, Sackeim HA, Nobler MS, Moeller JR. Brain imaging studies of antidepressant treatments. Psychiatr Ann. 1994;24:653–658
  128. Rush AJ, Weissenburger JE. Melancholic symptom features and DSM-IV. Am. J. Psychiatry. 1994;151:489–498
  129. Rush AJ, Giles DE, Schlesser MA, Orsulak PJ, Parker CR, Weissenburger JE, et al. The dexamethasone suppression test in patients with mood disorders. J. Clin. Psychiatry. 1996;57:470–484
  130. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N. Engl. J. Med. 2006;354:1231–1242
  131. Sackeim HA, Haskett RF, Mulsant BH, Thase ME, Mann JJ, Pettinati HM, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA. 2001;285:1299–1307
  132. Sanders AR, Detera-Wadleigh SD, Gershon ES. Molecular genetics of mood disorders. In:  Charney DS,  Nestler EJ,  Bunney BS editor. Neurobiology of Mental Illness. New York: Oxford University Press; 1999;
  133. Sargent PA, Kjaer KH, Bench CJ, Rabiner EA, Messa C, Meyer J, et al. Brain serotonin 1A receptor finding measured by positron tomography with [11c]WAY-100635: effects of depression and antidepressant treatment. Arch. Gen. Psychiatry. 2000;57:174–180
  134. Saxena S, Brody AL, Ho ML, Alborzian S, Ho MK, Maidment KM, et al. Cerebral metabolism in major depression and obsessive-compulsive disorder occurring separately and concurrently. Biol. Psychiatry. 2001;50:159–170
  135. Saxena S, Brody AL, Ho ML, Alborzian S, Maidment KM, Zohrabi N, et al. Differential cerebral metabolic changes with paroxetine treatment of obsessive-compulsive disorder vs. major depression. Arch. Gen. Psychiatry. 2002;59:250–261
  136. Schatzberg AF. Noradrenergic versus serotonergic antidepressants: predictors of treatment response. J. Clin. Psychiatry. 1998;59(suppl 14):15–18
  137. Schneider F, Gur RE, Mozley LH, Smith RJ, Mozley PD, Censits DM, et al. Mood effects on limbic blood flow correlate with emotional self-rating: a PET study with oxygen-15 labeled water. Psychiatry Res. 1995;61:265–283
  138. Shah PJ, Ebmeier KP, Glabus MF, Goodwin GM. Cortical grey matter reductions associated with treatment-resistant chronic unipolar depression: controlled magnetic resonance imaging study. Br. J. Psychiatry. 1998;172:527–532
  139. Sheline YI, Wang PW, Gado MH, Csernansky JG, Vannier MW. Hippocampal atrophy in recurrent major depression. Proc. Natl. Acad. Sci. 1996;93:908–913
  140. Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am. J. Psychiatry. 2003;160:1515–1518
  141. Silverman C. The epidemiology of depression. A review. Am. J. Psychiatry. 1968;124:883–891
  142. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta—analysis. Am. J. Psychiatry. 2001;157:1552–1562
  143. Sullivan PF, Prescott CA, Kendler KS. The subtypes of major depression in a twin registry. J. Affect. Disord. 2002;68:273–284
  144. Taylor MA, Abrams R. Reassessing the bipolar-unipolar dichotomy. J. Affect. Disord. 1980;2:195–217
  145. Taylor MA, Fink M. Melancholia: The Diagnosis, Pathophysiology, and Treatment of Depressive Illness. Cambridge UK: Cambridge University Press; 2006;
  146. Taylor MA, Abrams R, Hayman M. The classification of affective disorder: A reassessment of the bipolar–unipolar dichotomy; Part 1: A clinical, laboratory and family study. J. Affect. Disord. 1980;2:95–109
  147. Thase ME. Effectiveness of antidepressants: comparative remission rates. J. Clin. Psychiatry. 2003;64(suppl 2):3–7
  148. Todd RD, Neuman R, Geller B, Fox LW, Hickok J. Genetic studies of affective disorders: should we be starting with childhood onset probands?. J. Am. Acad. Child Adolesc. Psych. 1993;32:1164–1171
  149. Torgersen S. Genetic factors in moderately severe and mild affective disorders. Arch. Gen. Psychiatry. 1986;43:222
  150. Tsuang MT, Faraone SV. The Genetics of Mood Disorders. Baltimore: Johns Hopkins University Press; 1990;
  151. Tsuang MT, Faraone SV, Green RR. Genetic epidemiology of mood disorders. In:  Papolos DF,  Lachman HM editor. Genetic Studies in Affective Disorders. New York: Wiley; 1994;
  152. Van de Kar LD, Blair ML. Forebrain pathways mediating stress-induced hormone secretion. Front. Neuroendocrinol. 1999;20:1–48
  153. Weissman MM. Psychopathology in the children of depressed parents: direct interview studies. In:  Dunner DL,  Gershon ES,  Barrett JB editor. Relatives at Risk for Mental Disorder. New York, NY: Raven Press; 1988;p. 143–159
  154. Weissman MM, Gershon ES, Kidd KK, Prusoff BA, Leckman JF, Dibble E, et al. Psychiatric disorders in the relatives of probands with affective disorder. Arch. Gen. Psychiatry. 1984;41:13–21
  155. Weissman MM, Warner V, Wickramaratne P, Prusoff BA. Early-onset major depression in parents and their children. J. Affect. Disord. 1988;15:269–277
  156. Williamson DE, Birmaher B, Axelson DA, Ryan ND, Dahl RE. First episode of depression in children at low and high familial risk for depression. J. Am. Acad. Child Adolesc. Psych. 2004;43:291–297
  157. Winokur G, Coryell W. Familial subtypes of unipolar depression: a prospective study of familial pure depressive disease compared to depressive spectrum disease. Biol. Psychiatry. 1992;32:1012–1018
  158. Wu JC, Gillin JC, Buchsbaum MS, Hershey T, Johnson JC, Bunney WE. Effect of sleep deprivation on brain metabolism of depressed patients. Am. J. Psychiatry. 1992;149:538–543
  159. Yehuda R, Boisoneau D, Mason JW, Giller EL. Glucocorticoid receptor number and cortisol excretion in mood, anxiety and psychotic disorders. Biol. Psychiatry. 1993;34:18–25
  160. Yerevanian BI, Feusner JD, Koek RJ, Mintz J. The dexamethasone suppression test as a predictor of suicidal behavior in unipolar depression. J. Affect. Disord. 2004;83:103–108
  161. Young MA, Scheftner WA, Klerman GL, Andreasen NC, Hirschfeld RMA. The endogenous sub-type of depression: a study of its internal construct validity. Br. J. Psychiatry. 1986;148:257–267
  162. Young MA, Keller MB, Lavori PW, Scheftner Wa, Fawcett Ja, Endicott J, et al. Lack of stability of the RDC endogenous subtype in consecutive episodes of major depression. J. Affect. Disord. 1987;12:139–143
  163. Young EA, Haskett RF, Murphy-Weinberg V, Watson SJ, Akil H. Loss of glucocorticoid fast feedback in depression. Arch. Gen. Psychiatry. 1991;48:693–699
  164. Zimmerman M, Coryell W, Pfohl B, Stangi D. The validity of four definitions of endogenous depression. Arch. Gen. Psychiatry. 1986;43:234

PII: S0165-0327(07)00215-7

doi: 10.1016/j.jad.2007.05.023

Journal of Affective Disorders
Volume 105, Issue 1 , Pages 1-14 , January 2008

Article Tools